Brief: Ambrx Provides Update On Apex-01, An On-Going Phase 1 / 2 Dose Escalation Study Evaluating Arx517, A Proprietary Psma-Targeting Adc, In Metastatic Castration-Resistant Prostate Cancer

Ambrx Biopharma

28/11/2023 15:12

Nov 28 (Reuters) - Ambrx Biopharma Inc  AMAM.O :
    * AMBRX PROVIDES UPDATE ON APEX-01, AN ON-GOING PHASE 1 / 2
DOSE
ESCALATION STUDY EVALUATING ARX517, A PROPRIETARY PSMA-TARGETING
ADC, IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    * AMBRX BIOPHARMA CAYMAN - TWO PATIENTS IN COHORT 9
EXPERIENCED
RAPID PSA REDUCTION AT THREE WEEKS POST-TREATMENT FOLLOWING
FIRST ARX517 DOSE COHORT 8
    * AMBRX BIOPHARMA CAYMAN - TWO PATIENTS IN COHORT 9
EXPERIENCED
RAPID PSA REDUCTION AT THREE WEEKS POST-TREATMENT FOLLOWING
FIRST ARX517 DOSE COHORT 8
    * AMBRX BIOPHARMA CAYMAN:AFTER COMPLETION OF 21-DAY
OBSERVATION
PERIOD AT 3.4 MG/KG, NO DOSE LIMITING TOXICITIES O, SERIOUS
ADVERSE EVENTS WERE OBSERVED
    * AMBRX BIOPHARMA CAYMAN INC - COHORT 8 IS NOW FULLY
ENROLLED WITH
20 PATIENTS
    * AMBRX BIOPHARMA CAYMAN INC -  COHORT 8 RECOMMENDED PHASE 2
DOSE
EXPECTED BY EARLY NEXT YEAR

Source text for Eikon:  ID:nGNX83qyjR 
Further company coverage:  AMAM.O 

 ((Reutersbriefs@thomsonreuters.com;))